On Thursday, the FDA announced that it is taking new steps in 2018 to make the development and approval of biosimilars more efficient.
On Thursday, the FDA announced that it is taking new steps in 2018 to make the development and approval of biosimilars more efficient.
In its 2018 Strategic Policy Roadmap, the agency said that it will launch a Biosimilar Innovation Plan this year. As part of the overall effort, the FDA reports that its plan will “create better incentives” for the adoption of biosimilars as a way to spur greater competition among and reduce the costs of biologic therapies. “Greater access to effective drugs also helps advance the public health and lower overall healthcare costs by improving health outcomes and reducing the cost and burden of disease,” said the FDA’s Roadmap, adding that enabling access to innovative drugs is a critical aspect of the agency’s mandate.
The agency is also taking steps to facilitate greater generic drug competition as part of its existing Drug Competition Action Plan, and says that it will, among other steps:
The agency also announced that it will issue final guidance on product developers’ communications with payers about the economic consequences of their products (which may promote value-based contracting), and will establish an inter-agency working group to explore areas where the FDA can collaborate with the Federal Trade Commission on issues related to competition.
In a statement, FDA Commissioner Scott Gottlieb, MD, said, “In focusing on these selected efforts, we will optimize our resources to achieve clear deliverables that will yield results over the next [2] years.” He added, “Publishing this Roadmap is another way that we aim to provide more transparency about the FDA’s policy undertakings to all our stakeholders.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.